GEN Exclusives

More »

GEN News Highlights

More »
Oct 4, 2011

Servier and Galapagos Embark on Cancer Drug Alliance Valued at €260M

  • Servier and Galapagos inked multiyear partnership worth potentially €260 million (about $348 million) and focused on developing cancer therapeutics against targets discovered by both firms. Under terms of the deal, Galapagos will receive research access payments of €2 million and will be responsible for the discovery and development of new drug candidates.

    Servier has an exclusive option to license each small molecule program after preclinical development by its partner and will be responsible for further worldwide (except the U.S.) clinical development, registration, and commercialization for any program it licenses. Galapagos will retain exclusive U.S. development and commercialization rights to resulting products.

    Galapagos and Servier already have an ongoing osteoarthritis drug discovery and development alliance, which was initiated in July 2010. Under terms of this deal Galapagos retains exclusive U.S. commercialization rights to any marketed products.


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Ebola Vaccines

When do you think an Ebola vaccine will be available for the general public?